| Code | Description | Claims | Beneficiaries | Total Paid |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
99,901 |
48,240 |
$16.94M |
| 87070 |
|
33,699 |
31,150 |
$16.37M |
| 80053 |
Comprehensive metabolic panel |
32,632 |
29,387 |
$15.64M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
92,792 |
40,474 |
$11.56M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
38,913 |
36,035 |
$10.22M |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
27,347 |
26,742 |
$10.03M |
| 81001 |
|
30,654 |
26,970 |
$9.33M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
35,233 |
15,908 |
$8.30M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
9,400 |
7,726 |
$5.95M |
| 36415 |
Collection of venous blood by venipuncture |
11,299 |
9,500 |
$5.61M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
62,438 |
30,216 |
$5.37M |
| 71046 |
Radiologic examination, chest; 2 views |
32,611 |
15,314 |
$4.73M |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
25,191 |
22,591 |
$4.47M |
| 80076 |
|
7,402 |
6,339 |
$4.16M |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
7,770 |
7,340 |
$3.77M |
| 86580 |
|
6,583 |
6,425 |
$3.73M |
| 99442 |
|
5,430 |
4,463 |
$3.60M |
| 99443 |
|
4,061 |
3,530 |
$2.68M |
| 80048 |
Basic metabolic panel (calcium, ionized) |
6,612 |
6,155 |
$2.67M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
8,356 |
7,147 |
$2.23M |
| 80061 |
Lipid panel |
11,863 |
11,537 |
$2.11M |
| 86480 |
|
8,107 |
7,941 |
$2.11M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
10,057 |
5,418 |
$2.03M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
6,445 |
5,840 |
$1.61M |
| 85027 |
|
10,012 |
9,621 |
$1.41M |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
4,707 |
3,822 |
$1.41M |
| 99441 |
|
2,062 |
1,786 |
$1.38M |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,893 |
3,339 |
$1.34M |
| 87631 |
|
3,656 |
3,462 |
$1.34M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
7,887 |
6,899 |
$1.30M |
| 81025 |
|
12,686 |
11,568 |
$1.28M |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,926 |
1,643 |
$1.27M |
| 73130 |
|
5,169 |
2,281 |
$1.25M |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
13,694 |
13,394 |
$1.23M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
7,181 |
6,177 |
$1.12M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
44,017 |
39,284 |
$1.10M |
| 99241 |
|
1,726 |
1,652 |
$1.03M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
41,705 |
19,676 |
$1.00M |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
1,562 |
1,455 |
$900K |
| 86803 |
|
6,473 |
6,250 |
$891K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,818 |
1,664 |
$847K |
| 86703 |
|
12,328 |
11,953 |
$799K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
1,058 |
1,030 |
$782K |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
1,471 |
1,239 |
$711K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
5,613 |
1,730 |
$702K |
| 73562 |
|
2,849 |
1,387 |
$701K |
| 82950 |
|
2,741 |
2,672 |
$677K |
| 84702 |
|
4,003 |
3,172 |
$675K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
3,525 |
3,480 |
$669K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
4,922 |
3,507 |
$656K |
| 73610 |
|
2,733 |
1,265 |
$649K |
| 85018 |
|
1,611 |
1,569 |
$644K |
| 73630 |
|
2,622 |
1,243 |
$624K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
5,545 |
2,754 |
$624K |
| 86592 |
|
4,856 |
4,699 |
$615K |
| 82105 |
|
1,670 |
1,637 |
$609K |
| 80074 |
|
2,234 |
2,149 |
$573K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,761 |
2,504 |
$560K |
| 92567 |
|
2,607 |
2,542 |
$546K |
| 82728 |
|
4,090 |
3,970 |
$539K |
| 83520 |
|
2,668 |
1,787 |
$528K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
791 |
718 |
$515K |
| 73030 |
|
2,323 |
1,093 |
$498K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
4,606 |
4,559 |
$485K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
4,772 |
2,350 |
$479K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
649 |
498 |
$478K |
| 82607 |
|
2,558 |
2,504 |
$476K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
4,125 |
3,279 |
$475K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
980 |
927 |
$470K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,808 |
872 |
$465K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,431 |
3,371 |
$450K |
| 84439 |
|
4,039 |
3,906 |
$449K |
| 85652 |
|
2,866 |
2,704 |
$437K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,690 |
2,665 |
$423K |
| Q0144 |
Azithromycin dihydrate, oral, capsules/powder, 1 gram |
994 |
968 |
$417K |
| H2010 |
Comprehensive medication services, per 15 minutes |
672 |
567 |
$397K |
| 76801 |
|
5,345 |
2,480 |
$391K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,040 |
990 |
$379K |
| 90632 |
|
429 |
422 |
$356K |
| 70450 |
Computed tomography, head or brain; without contrast material |
5,236 |
2,543 |
$347K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
14,007 |
13,617 |
$343K |
| 73110 |
|
1,482 |
655 |
$342K |
| 77066 |
Tomosynthesis, mammo |
1,842 |
1,079 |
$337K |
| 92557 |
|
540 |
529 |
$318K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,985 |
1,871 |
$295K |
| 92553 |
|
391 |
380 |
$293K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
3,788 |
2,735 |
$289K |
| 87077 |
|
4,455 |
4,061 |
$283K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
2,233 |
1,121 |
$274K |
| 84443 |
Thyroid stimulating hormone (TSH) |
11,591 |
11,137 |
$266K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
11,065 |
10,922 |
$232K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,868 |
1,831 |
$215K |
| 82043 |
|
2,563 |
2,490 |
$188K |
| 73140 |
|
673 |
317 |
$181K |
| 73090 |
|
774 |
320 |
$168K |
| 73000 |
|
507 |
237 |
$163K |
| 76830 |
Ultrasound, transvaginal |
990 |
490 |
$149K |
| 73590 |
|
627 |
273 |
$144K |
| 72100 |
|
927 |
460 |
$140K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
154 |
152 |
$125K |
| 86140 |
|
13,515 |
12,312 |
$121K |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
1,434 |
1,287 |
$117K |
| 70486 |
|
1,657 |
799 |
$113K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
1,363 |
1,158 |
$107K |
| 87040 |
|
6,030 |
4,539 |
$99K |
| 82570 |
|
4,901 |
4,420 |
$97K |
| 87340 |
|
4,637 |
4,529 |
$96K |
| 82272 |
|
315 |
297 |
$95K |
| 85610 |
|
4,659 |
4,360 |
$94K |
| 99173 |
|
660 |
655 |
$93K |
| 84145 |
|
3,356 |
3,160 |
$92K |
| 86780 |
|
9,491 |
9,187 |
$88K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
9,988 |
9,387 |
$82K |
| 93000 |
|
5,783 |
5,246 |
$82K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
176 |
160 |
$81K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
533 |
323 |
$80K |
| 88142 |
|
1,490 |
1,463 |
$80K |
| 73560 |
|
383 |
186 |
$76K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
2,698 |
1,330 |
$73K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
749 |
728 |
$72K |
| 92552 |
|
99 |
98 |
$71K |
| 74018 |
|
794 |
382 |
$66K |
| 73080 |
|
297 |
135 |
$65K |
| 99215 |
Prolong outpt/office vis |
728 |
368 |
$62K |
| 76642 |
|
420 |
209 |
$61K |
| 87400 |
|
166 |
153 |
$54K |
| 76770 |
|
326 |
158 |
$54K |
| 92002 |
|
71 |
71 |
$51K |
| 85370 |
|
2,881 |
2,745 |
$51K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
958 |
922 |
$50K |
| 97161 |
|
2,012 |
1,967 |
$50K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
225 |
208 |
$46K |
| 83880 |
|
2,928 |
2,654 |
$42K |
| 90791 |
Psychiatric diagnostic evaluation |
66 |
66 |
$41K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
2,893 |
1,405 |
$40K |
| 71045 |
Radiologic examination, chest; single view |
2,195 |
1,039 |
$39K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,498 |
1,780 |
$38K |
| J1756 |
Injection, iron sucrose, 1 mg |
63 |
27 |
$38K |
| 92587 |
|
855 |
838 |
$36K |
| 82150 |
|
397 |
378 |
$36K |
| 92555 |
|
121 |
118 |
$36K |
| 97162 |
|
1,307 |
1,270 |
$36K |
| 96381 |
|
44 |
37 |
$34K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
283 |
142 |
$34K |
| 82951 |
|
93 |
92 |
$31K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
734 |
723 |
$31K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
82 |
76 |
$30K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
41 |
38 |
$28K |
| J3490 |
Unclassified drugs |
111 |
99 |
$28K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
465 |
230 |
$27K |
| 11982 |
|
112 |
111 |
$27K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
1,673 |
814 |
$27K |
| 71250 |
|
176 |
87 |
$27K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
29 |
29 |
$27K |
| 84550 |
|
1,263 |
1,126 |
$27K |
| 84153 |
|
213 |
208 |
$26K |
| 84484 |
|
3,911 |
3,125 |
$24K |
| 86885 |
|
5,113 |
4,625 |
$23K |
| 83735 |
|
4,330 |
3,911 |
$20K |
| 92551 |
|
33 |
33 |
$19K |
| 91320 |
|
31 |
31 |
$19K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
482 |
411 |
$18K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
90 |
77 |
$17K |
| 83690 |
|
5,294 |
4,759 |
$17K |
| 73502 |
|
126 |
61 |
$16K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
25 |
24 |
$16K |
| 92523 |
|
124 |
121 |
$16K |
| 86038 |
|
215 |
213 |
$15K |
| 82542 |
|
4,137 |
2,807 |
$15K |
| 82550 |
|
1,007 |
921 |
$14K |
| 84156 |
|
2,277 |
1,852 |
$14K |
| 83655 |
|
26 |
25 |
$13K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
14 |
13 |
$13K |
| 83021 |
|
108 |
108 |
$13K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
18 |
18 |
$12K |
| 82565 |
|
853 |
760 |
$11K |
| J2560 |
Injection, phenobarbital sodium, up to 120 mg |
131 |
107 |
$11K |
| 87420 |
|
127 |
113 |
$9K |
| 10060 |
|
675 |
637 |
$9K |
| 83540 |
|
3,775 |
3,661 |
$9K |
| 97163 |
|
42 |
42 |
$9K |
| 82157 |
|
13 |
13 |
$8K |
| 84480 |
|
26 |
26 |
$8K |
| V5011 |
Fitting/orientation/checking of hearing aid |
13 |
13 |
$8K |
| 87517 |
|
36 |
36 |
$8K |
| 99243 |
|
18 |
18 |
$8K |
| 97010 |
|
12 |
12 |
$8K |
| 84075 |
|
73 |
70 |
$7K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
140 |
126 |
$7K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
32 |
16 |
$7K |
| 11981 |
|
66 |
66 |
$7K |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
14 |
12 |
$7K |
| 82731 |
|
75 |
74 |
$7K |
| 73120 |
|
57 |
29 |
$7K |
| 59025 |
Fetal non-stress test |
2,759 |
2,104 |
$6K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
34,202 |
31,737 |
$6K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
652 |
639 |
$6K |
| 97602 |
|
42 |
28 |
$6K |
| 86431 |
|
302 |
292 |
$6K |
| 86708 |
|
14 |
12 |
$5K |
| 97167 |
|
26 |
24 |
$5K |
| G0378 |
Hospital observation service, per hour |
51 |
49 |
$5K |
| 82677 |
|
1,037 |
1,018 |
$5K |
| 90746 |
|
30 |
30 |
$5K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
54 |
27 |
$5K |
| V5020 |
Conformity evaluation |
13 |
13 |
$4K |
| 87507 |
|
13 |
13 |
$4K |
| 73600 |
|
30 |
13 |
$4K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
902 |
655 |
$3K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
28 |
12 |
$3K |
| 87556 |
|
15 |
14 |
$3K |
| 82784 |
|
12 |
12 |
$3K |
| 86900 |
|
5,033 |
4,685 |
$3K |
| 86706 |
|
276 |
264 |
$3K |
| 83605 |
|
3,937 |
3,338 |
$3K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
135 |
124 |
$3K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
4,008 |
3,658 |
$3K |
| 20610 |
|
33 |
28 |
$3K |
| 92015 |
Determination of refractive state |
106 |
103 |
$2K |
| 86765 |
|
2,911 |
2,862 |
$2K |
| 87205 |
|
647 |
583 |
$2K |
| 76818 |
|
15 |
14 |
$2K |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
3,140 |
2,886 |
$2K |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
225 |
217 |
$2K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
230 |
112 |
$2K |
| 82746 |
|
1,921 |
1,885 |
$2K |
| 58300 |
|
85 |
81 |
$2K |
| Q3014 |
Telehealth originating site facility fee |
28 |
28 |
$1K |
| 99234 |
|
2,837 |
2,216 |
$1K |
| 92504 |
|
539 |
525 |
$1K |
| G8981 |
Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals |
244 |
242 |
$1K |
| G8982 |
Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
258 |
256 |
$1K |
| 85008 |
|
302 |
281 |
$1K |
| 97166 |
|
14 |
14 |
$1K |
| 84132 |
|
13 |
12 |
$945.00 |
| 87536 |
|
12 |
12 |
$862.00 |
| 12001 |
|
72 |
71 |
$710.00 |
| 12011 |
|
12 |
12 |
$710.00 |
| 74022 |
|
58 |
27 |
$682.00 |
| 92591 |
|
13 |
13 |
$682.00 |
| 86200 |
|
70 |
66 |
$653.00 |
| 86901 |
|
5,032 |
4,684 |
$0.00 |
| 90480 |
|
469 |
460 |
$0.00 |
| 85660 |
|
84 |
84 |
$0.00 |
| 80329 |
|
3,345 |
2,775 |
$0.00 |
| 83550 |
|
3,292 |
3,204 |
$0.00 |
| 99235 |
|
674 |
608 |
$0.00 |
| 90474 |
|
1,764 |
1,751 |
$0.00 |
| 83789 |
|
5,932 |
4,805 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
188 |
173 |
$0.00 |
| 80320 |
|
6,181 |
5,604 |
$0.00 |
| 82803 |
|
150 |
118 |
$0.00 |
| 96376 |
|
769 |
737 |
$0.00 |
| 85379 |
|
64 |
62 |
$0.00 |
| 70498 |
|
54 |
27 |
$0.00 |
| 0134A |
|
140 |
137 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
22 |
14 |
$0.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
33 |
28 |
$0.00 |
| 87081 |
|
12 |
12 |
$0.00 |
| 83498 |
|
13 |
13 |
$0.00 |
| 81374 |
|
17 |
16 |
$0.00 |
| 74019 |
|
52 |
26 |
$0.00 |
| 99403 |
|
12 |
12 |
$0.00 |
| 81420 |
Fetal chromosomal aneuploidy genomic sequence analysis panel |
379 |
367 |
$0.00 |
| 84100 |
|
242 |
214 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
49 |
44 |
$0.00 |
| 84520 |
|
675 |
605 |
$0.00 |
| 86336 |
|
1,024 |
1,005 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
242 |
234 |
$0.00 |
| 96367 |
|
28 |
26 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
667 |
653 |
$0.00 |
| 51701 |
|
17 |
17 |
$0.00 |
| 99222 |
Initial hospital care, per day, moderate complexity |
13 |
12 |
$0.00 |
| 86235 |
|
19 |
14 |
$0.00 |
| 0124A |
|
162 |
160 |
$0.00 |
| 98960 |
|
32 |
24 |
$0.00 |
| 87075 |
|
167 |
165 |
$0.00 |
| 0071A |
|
76 |
76 |
$0.00 |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
13 |
13 |
$0.00 |
| 91322 |
|
47 |
47 |
$0.00 |
| 29125 |
|
16 |
15 |
$0.00 |
| 82977 |
|
12 |
12 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
18 |
13 |
$0.00 |
| 87653 |
|
13 |
13 |
$0.00 |
| 90473 |
|
14 |
14 |
$0.00 |
| 99221 |
|
15 |
13 |
$0.00 |
| 86003 |
|
12 |
12 |
$0.00 |
| 91321 |
|
15 |
15 |
$0.00 |
| 87150 |
|
12 |
12 |
$0.00 |
| 10061 |
|
12 |
12 |
$0.00 |